Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이화정 | * |
dc.date.accessioned | 2018-12-14T16:30:46Z | - |
dc.date.available | 2018-12-14T16:30:46Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0167-6806 | * |
dc.identifier.other | OAK-22692 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247694 | - |
dc.description.abstract | Purpose: This meta-analysis investigated the association between the risk of breast cancer and hormone replacement therapy (HRT). Various stratified analyses were performed according to race (Asian/Westerner), HRT type [all hormone therapies, estrogen-only therapy (ET), or combined estrogen–progestin therapy (EPT)], histological breast cancer type (ductal/lobular/mixed ductal–lobular), and estrogen receptor status (ER-positive/ER-negative). Methods: A literature search was performed using Pubmed, Embase, and KoreaMed. Twenty-five epidemiological studies including 23 cohort studies and two randomized controlled trials were included in this meta-analysis. Results: Using a random-effects model, HRT use was found to be positively associated with the risk of breast cancer with a pooled hazard ratio (HR) of 1.33 [95% confidence interval (CI) 1.24, 1.44]. Compared with ET, EPT was more strongly associated with breast cancer risk. EPT was associated with both ductal and lobular breast cancer risks [for ductal breast cancer, HR = 1.51 (95% CI 1.28, 1.78); for lobular breast cancer, HR = 1.38 (95% CI 1.20, 1.60)]. According to ER status, all HRTs were associated with the risk of ER-positive breast cancer, but not with that of ER-negative breast cancer. Conclusions: Asian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. | * |
dc.language | English | * |
dc.publisher | Springer New York LLC | * |
dc.subject | Breast cancer | * |
dc.subject | Hormone replacement therapy | * |
dc.subject | Menopausal hormone therapy | * |
dc.subject | Meta-analysis | * |
dc.title | Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 170 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 667 | * |
dc.relation.lastpage | 675 | * |
dc.relation.journaltitle | Breast Cancer Research and Treatment | * |
dc.identifier.doi | 10.1007/s10549-018-4782-2 | * |
dc.identifier.wosid | WOS:000436799000023 | * |
dc.identifier.scopusid | 2-s2.0-85049148790 | * |
dc.author.google | Kim S. | * |
dc.author.google | Ko Y. | * |
dc.author.google | Lee H.J. | * |
dc.author.google | Lim J.-E. | * |
dc.contributor.scopusid | 이화정(57102029300) | * |
dc.date.modifydate | 20240118154655 | * |